YahooSeptember 3, 2026 at 9:24 PM NY14 hours ago
AbbVie (ABBV)’s Blood Cancer Success Adds Weight to its Pipeline Story
AbbVie Inc. (NYSE:ABBV)’s experimental blood-cancer therapy etentamig delivered positive results in a late-stage trial for patients with relapsed or refractory multiple myeloma, meeting the trial’s main objectives. The drug produced an objective response rate of 74%, compared with 45.7% for standard treatments selected by investigators. More importantly, etentamig reduced the risk of disease progression or […]
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo
Companies in This Story
Related Stories
AbbVie’s Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing?
Yahoo1 hour ago
Anthropic's IPO Push Just Got a $15 Billion Backstop
Yahoo30 minutes ago
2 Services Stocks with Promising Prospects and 1 We Ignore
Yahoo31 minutes ago
Anthropic Follows SpaceX's Playbook With a $15 Billion Revolver
Yahoo33 minutes ago
VEVOR Steps Offline in Europe at IFA Berlin 2026, with First European Store Planned in France for 2027
Yahoo35 minutes ago